Nautilus Biotechnology Inc. $(NAUT)$ reported its financial results for the second quarter of 2025. The company achieved a net loss of $15.0 million, an improvement from the $18.0 million net loss in the same quarter of the previous year. Operating expenses decreased by 18% to $17.1 million, down from $20.8 million in the prior year period, driven by efforts in cost optimization and reduced expenses in salaries, benefits, stock-based compensation, and professional services. Nautilus Biotechnology's cash, cash equivalents, and investments totaled $179.5 million as of June 30, 2025. The company highlighted significant progress in its proteome analysis platform, including sharing a scientific manuscript that introduces and validates their Iterative Mapping method. Additionally, Nautilus announced collaborations with major research institutes to further explore Alzheimer's disease through their platform and Tau proteoform assay.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。